Literature DB >> 27548641

Lack of evidence of rotavirus-dependent molecular mimicry as a trigger of coeliac disease.

F Ziberna1, G De Lorenzo2, V Schiavon3, F Arnoldi4, S Quaglia1, L De Leo1, S Vatta1, S Martelossi1, O R Burrone2, A Ventura1,4, T Not1,4.   

Abstract

New data suggest the involvement of rotavirus (RV) in triggering autoimmunity in coeliac disease (CD) by molecular mimicry between the human-transglutaminase protein and the dodecapeptide (260-271 aa) of the RV protein VP7 (pVP7). To assess the role of RV in the onset of CD, we measured anti-pVP7 antibodies in the sera of children with CD and of control groups. We analysed serum samples of 118 biopsy-proven CD patients and 46 patients with potential CD; 32 children with other gastrointestinal diseases; 107 no-CD children and 107 blood donors. Using enzyme-linked immunosorbent assay (ELISA) assay, we measured immunoglobulin (Ig)A-IgG antibodies against the synthetic peptides pVP7, the human transglutaminase-derived peptide (476-487 aa) which shows a homology with VP7 protein and a control peptide. The triple-layered RV particles (TLPs) containing the VP7 protein and the double-layered RV-particles (DLPs) lacking the VP7 protein were also used as antigens in ELISA assay. Antibody reactivity to the RV-TLPs was positive in 22 of 118 (18%) CD patients and in both paediatric (17 of 107, 16%) and adult (29 of 107, 27%) control groups, without showing a statistically significant difference among them (P = 0·6, P = 0·1). Biopsy-proven CD patients as well as the adult control group demonstrated a high positive antibody reactivity against both pVP7 (34 of 118, 29% CD patients; 66 of 107, 62% adult controls) and control synthetic peptides (35 of 118, 30% CD patients; 56 of 107, 52% adult controls), suggesting a non-specific response against RV pVP7. We show that children with CD do not have higher immune reactivity to RV, thus questioning the molecular mimicry mechanism as a triggering factor of CD.
© 2016 British Society for Immunology.

Entities:  

Keywords:  VP7; coeliac disease; molecular mimicry; rotavirus

Mesh:

Substances:

Year:  2016        PMID: 27548641      PMCID: PMC5108075          DOI: 10.1111/cei.12855

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Prevalence of celiac disease in patients with severe food allergy.

Authors:  R Pillon; F Ziberna; L Badina; A Ventura; G Longo; S Quaglia; L De Leo; S Vatta; S Martelossi; G Patano; T Not; I Berti
Journal:  Allergy       Date:  2015-07-27       Impact factor: 13.146

Review 2.  Molecular mechanisms in autoimmune type 1 diabetes: a critical review.

Authors:  Zhiguo Xie; Christopher Chang; Zhiguang Zhou
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

3.  Interaction of enterovirus infection and cow's milk-based formula nutrition in type 1 diabetes-associated autoimmunity.

Authors:  J Lempainen; S Tauriainen; O Vaarala; M Mäkelä; H Honkanen; J Marttila; R Veijola; O Simell; H Hyöty; M Knip; J Ilonen
Journal:  Diabetes Metab Res Rev       Date:  2012-02       Impact factor: 4.876

4.  Adenovirus 12 E1A gene detection by polymerase chain reaction in both the normal and coeliac duodenum.

Authors:  M Lawler; P Humphries; C O'Farrelly; H Hoey; O Sheils; M Jeffers; D S O'Briain; D Kelleher
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

5.  Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

Authors:  Syed Sohail Ahmed; Wayne Volkmuth; José Duca; Lorenzo Corti; Michele Pallaoro; Alfredo Pezzicoli; Anette Karle; Fabio Rigat; Rino Rappuoli; Vas Narasimhan; Ilkka Julkunen; Arja Vuorela; Outi Vaarala; Hanna Nohynek; Franco Laghi Pasini; Emanuele Montomoli; Claudia Trombetta; Christopher M Adams; Jonathan Rothbard; Lawrence Steinman
Journal:  Sci Transl Med       Date:  2015-07-01       Impact factor: 17.956

6.  Infections and risk of celiac disease in childhood: a prospective nationwide cohort study.

Authors:  Karl Mårild; Christian R Kahrs; German Tapia; Lars C Stene; Ketil Størdal
Journal:  Am J Gastroenterol       Date:  2015-09-08       Impact factor: 10.864

7.  A subset of anti-rotavirus antibodies directed against the viral protein VP7 predicts the onset of celiac disease and induces typical features of the disease in the intestinal epithelial cell line T84.

Authors:  Marzia Dolcino; Giovanna Zanoni; Caterina Bason; Elisa Tinazzi; Elisa Boccola; Enrico Valletta; Giovanna Contreas; Claudio Lunardi; Antonio Puccetti
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

8.  Possible role for a human adenovirus in the pathogenesis of celiac disease.

Authors:  M F Kagnoff; R K Austin; J J Hubert; J E Bernardin; D D Kasarda
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

9.  Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.

Authors:  Rasmus Iversen; Roberto Di Niro; Jorunn Stamnaes; Knut E A Lundin; Patrick C Wilson; Ludvig M Sollid
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

10.  Mechanistic insights into influenza vaccine-associated narcolepsy.

Authors:  S Sohail Ahmed; Lawrence Steinman
Journal:  Hum Vaccin Immunother       Date:  2016-03-31       Impact factor: 3.452

View more
  3 in total

Review 1.  New Insights into the Pathogenesis of Celiac Disease.

Authors:  Valli De Re; Raffaella Magris; Renato Cannizzaro
Journal:  Front Med (Lausanne)       Date:  2017-08-31

Review 2.  Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy.

Authors:  Gaetana Paolella; Silvia Sposito; Antonio Massimiliano Romanelli; Ivana Caputo
Journal:  Int J Mol Sci       Date:  2022-07-06       Impact factor: 6.208

Review 3.  Role of the gut microbiota in the pathogenesis of coeliac disease and potential therapeutic implications.

Authors:  Anthony K Akobeng; Parul Singh; Manoj Kumar; Souhaila Al Khodor
Journal:  Eur J Nutr       Date:  2020-07-10       Impact factor: 5.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.